Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 678.18
ACHN's Cash-to-Debt is ranked higher than
56% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ACHN: 678.18 )
Ranked among companies with meaningful Cash-to-Debt only.
ACHN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.1  Med: 227.35 Max: No Debt
Current: 678.18
Equity-to-Asset 0.97
ACHN's Equity-to-Asset is ranked higher than
97% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACHN: 0.97 )
Ranked among companies with meaningful Equity-to-Asset only.
ACHN' s Equity-to-Asset Range Over the Past 10 Years
Min: -6.98  Med: 0.68 Max: 0.97
Current: 0.97
-6.98
0.97
Piotroski F-Score: 2
Altman Z-Score: 31.37
Beneish M-Score: -2.04
WACC vs ROIC
18.46%
-1482.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -448.60
ACHN's Operating Margin % is ranked lower than
68% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ACHN: -448.60 )
Ranked among companies with meaningful Operating Margin % only.
ACHN' s Operating Margin % Range Over the Past 10 Years
Min: -17954.25  Med: -594.6 Max: 11879.49
Current: -448.6
-17954.25
11879.49
Net Margin % -425.36
ACHN's Net Margin % is ranked lower than
67% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. ACHN: -425.36 )
Ranked among companies with meaningful Net Margin % only.
ACHN' s Net Margin % Range Over the Past 10 Years
Min: -17897.17  Med: -553.66 Max: 12030.34
Current: -425.36
-17897.17
12030.34
ROE % -15.66
ACHN's ROE % is ranked higher than
65% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ACHN: -15.66 )
Ranked among companies with meaningful ROE % only.
ACHN' s ROE % Range Over the Past 10 Years
Min: -199.15  Med: -69.33 Max: -1.7
Current: -15.66
-199.15
-1.7
ROA % -15.17
ACHN's ROA % is ranked higher than
64% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. ACHN: -15.17 )
Ranked among companies with meaningful ROA % only.
ACHN' s ROA % Range Over the Past 10 Years
Min: -103.25  Med: -56.05 Max: -1.62
Current: -15.17
-103.25
-1.62
ROC (Joel Greenblatt) % -1562.34
ACHN's ROC (Joel Greenblatt) % is ranked lower than
68% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. ACHN: -1562.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACHN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6041.18  Med: -2833.51 Max: -287.49
Current: -1562.34
-6041.18
-287.49
3-Year EBITDA Growth Rate -10.60
ACHN's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. ACHN: -10.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACHN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.2 Max: 4.5
Current: -10.6
0
4.5
3-Year EPS without NRI Growth Rate -10.60
ACHN's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. ACHN: -10.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACHN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.5  Med: -26.6 Max: 3.4
Current: -10.6
-65.5
3.4
GuruFocus has detected 1 Warning Sign with Achillion Pharmaceuticals Inc $ACHN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACHN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SPPI, NAS:INO, NAS:NK, NAS:RXDX, OTCPK:SXMDF, NAS:WVE, NAS:OTIC, NAS:AKBA, NAS:VSAR, NAS:JNCE, NAS:AMAG, NAS:ANIP, NAS:RETA, NAS:AUPH, NAS:CYTK, NAS:PRTK, NAS:NTLA, NAS:CTMX, NAS:IMGN, NAS:CRSP » details
Traded in other countries:ADA.Germany,
Headquarter Location:USA
Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases like hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free.

Achillion Pharmaceuticals is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.

Top Ranked Articles about Achillion Pharmaceuticals Inc

Achillion to Present at the 2017 JMP Securities Life Sciences Conference
Achillion to Present at the Jefferies 2017 Global Healthcare Conference
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key mediator in the complement alternative pathway (AP). In addition, the USPTO has issued Notices of Allowance of four additional U.S. patent applications owned by Achillion, also with claims to compositions of matter, that are expected to issue as patents over the next few months. “Achillion’s aim is to establish a broad patent portfolio for its complement program. With the granting of this first patent we are pleased that the USPTO has confirmed that Achillion possesses a multitude of patentable complement factor D inhibitors,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. “As a leader in AP biology, we are proud to have been the first to clinically demonstrate, in healthy volunteers, the ability to suppress AP activity following oral dosing of our complement factor D inhibitor, ACH-4471. The receipt of this patent, along with a number of additional patent applications under review by the USPTO, strengthens our position as a leader in factor D inhibitors for the potential treatment of AP-mediated diseases, such as C3G, PNH and geographic atrophy.” About the Achillion Alternative Pathway Complement Factor D Platform Achillion has leveraged its internal discovery capabilities and a novel complement-related platform to develop small molecule factor D inhibitor compounds that target the complement AP. Factor D is an essential serine protease involved in the AP, a part of the innate immune system. Achillion's complement platform is focused on seeking to advance small molecule compounds that inhibit factor D and can potentially be used in the treatment of immune-related diseases in which the AP plays a critical role. Potential indications currently being evaluated for these compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and geographic atrophy (GA), an advanced form of dry age-related macular degeneration (dry AMD). About Achillion Pharmaceuticals Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com. Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Achillion may use words such as “expect,” “anticipate,” “project,” “target,” “intend,” “plan,” “aim,” “believe,” “seek,” “estimate,” “can,” “could,” “focus,” “will,” “look forward,” “goal,” “may,” “potential,” and similar expressions to identify such forward-looking statements. These forward-looking statements also include statements about: Achillion’s ability to obtain and maintain patent protection for its drug candidates and the expected benefit of its complement factor D inhibitor intellectual property portfolio; the potential benefits of, and potential indications for, Achillion’s compounds that inhibit factor D; and statements concerning Achillion’s strategic goals, efforts, plans, and prospects. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things, Achillion’s ability to: complete the patent process such that patents issue from the Notices of Allowance with respect to composition of matter claims for compounds that inhibit complement factor D activity; advance the preclinical and clinical development of its complement factor D inhibitors under the timelines it projects in current and future preclinical studies and clinical trials; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; obtain and maintain necessary regulatory approvals; establish commercial manufacturing arrangements; identify, enter into and maintain collaboration agreements with third-parties, including the current collaboration with Janssen; compete successfully in the markets in which it seeks to develop and commercialize its product candidates and future products; manage expenses; manage litigation; raise the substantial additional capital needed to achieve its business objectives; and successfully execute on its business strategies. These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and any subsequent SEC filings. In addition, any forward-looking statement in this press release represents Achillion's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Achillion disclaims any duty to update any forward-looking statement, except as required by applicable law.
Investors & Media:
Glenn Schulman, PharmD, MPH
Executive Director, Investor Relations
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
[email protected]

Read more...
Steven Cohen Increases Position in Dynavax Company is one of many biopharmaceutical holdings
Steven Cohen (Trades, Portfolio) of Point72 Asset Management increased his position in Dynavax Technologies Corp. (NASDAQ:DVAX) by 375.26% on Sept. 29. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.57
ACHN's PB Ratio is ranked higher than
83% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ACHN: 1.57 )
Ranked among companies with meaningful PB Ratio only.
ACHN' s PB Ratio Range Over the Past 10 Years
Min: 0.79  Med: 3.5 Max: 12.16
Current: 1.57
0.79
12.16
PS Ratio 39.82
ACHN's PS Ratio is ranked lower than
74% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. ACHN: 39.82 )
Ranked among companies with meaningful PS Ratio only.
ACHN' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 130.56 Max: 15990
Current: 39.82
0.77
15990
Current Ratio 36.07
ACHN's Current Ratio is ranked higher than
98% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ACHN: 36.07 )
Ranked among companies with meaningful Current Ratio only.
ACHN' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 7.28 Max: 36.07
Current: 36.07
1.06
36.07
Quick Ratio 36.07
ACHN's Quick Ratio is ranked higher than
98% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ACHN: 36.07 )
Ranked among companies with meaningful Quick Ratio only.
ACHN' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 7.28 Max: 36.07
Current: 36.07
1.06
36.07
Days Sales Outstanding 11.17
ACHN's Days Sales Outstanding is ranked higher than
88% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. ACHN: 11.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACHN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.79  Med: 124.65 Max: 371.23
Current: 11.17
2.79
371.23

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.20
ACHN's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ACHN: -12.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACHN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -274.8  Med: -35.85 Max: -12.2
Current: -12.2
-274.8
-12.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.63
ACHN's Price-to-Net-Cash is ranked higher than
91% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. ACHN: 1.63 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACHN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.82  Med: 4.83 Max: 12.7
Current: 1.63
0.82
12.7
Price-to-Net-Current-Asset-Value 1.61
ACHN's Price-to-Net-Current-Asset-Value is ranked higher than
91% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ACHN: 1.61 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACHN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.78  Med: 4.64 Max: 12.29
Current: 1.61
0.78
12.29
Price-to-Tangible-Book 1.57
ACHN's Price-to-Tangible-Book is ranked higher than
86% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. ACHN: 1.57 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACHN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72  Med: 4.13 Max: 81.84
Current: 1.57
0.72
81.84
Price-to-Median-PS-Value 0.30
ACHN's Price-to-Median-PS-Value is ranked higher than
88% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ACHN: 0.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACHN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.63 Max: 67.31
Current: 0.3
0.01
67.31
Earnings Yield (Greenblatt) % -28.90
ACHN's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. ACHN: -28.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACHN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1452.9  Med: -11.9 Max: 2697.4
Current: -28.9
-1452.9
2697.4

More Statistics

Revenue (TTM) (Mil) $15.00
EPS (TTM) $ -0.47
Beta2.72
Short Percentage of Float8.31%
52-Week Range $3.15 - 9.50
Shares Outstanding (Mil)136.72

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 38 130 25
EPS ($) -0.16 0.52 -0.07
EPS without NRI ($) -0.16 0.52 -0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
Achillion to Present at the 2017 JMP Securities Life Sciences Conference Jun 15 2017 
Achillion to Present at the Jefferies 2017 Global Healthcare Conference Jun 05 2017 
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs May 04 2017 
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference May 02 2017 
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks Apr 22 2017 
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturn Apr 06 2017 
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pat Mar 21 2017 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 

More From Other Websites
Achillion Pharmaceuticals Financials, Price Targets and Pipeline Review Jun 22 2017
Achillion to Present at the 2017 JMP Securities Life Sciences Conference Jun 15 2017
Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue? Jun 09 2017
Achillion to Present at the Jefferies 2017 Global Healthcare Conference Jun 05 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Jun 05 2017
Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx May 19 2017
Why Achillion Pharmaceuticals Stock Is Jumping 15% Today May 18 2017
Achillion: It Can't Get Any Worse…Or Can It? May 18 2017
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : May 11, 2017 May 11 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... May 10 2017
Achillion (ACHN) Reports Wider-than-Expected Loss in Q1 May 08 2017
Achillion reports 1Q loss May 04 2017
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs May 04 2017
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference May 02 2017
ETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017 Apr 25 2017
Why Achillion Pharmaceuticals Stock Sank on Monday Apr 25 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Apr 25 2017
Why Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today Apr 24 2017
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks... Apr 22 2017
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss Apr 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}